Home » Stocks » IFRX

InflaRx N.V. (IFRX)

Stock Price: $5.89 USD 0.33 (5.85%)
Updated Jan 19, 2021 3:44 PM EST - Market open
Market Cap 156.95M
Revenue (ttm) n/a
Net Income (ttm) -53.25M
Shares Out 26.00M
EPS (ttm) -1.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $5.89
Previous Close $5.56
Change ($) 0.33
Change (%) 5.85%
Day's Open 5.76
Day's Range 5.71 - 6.07
Day's Volume 286,204
52-Week Range 2.65 - 8.96

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

JENA, Germany, Jan. 11, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system...

GlobeNewsWire - 1 week ago

JENA, Germany, Jan. 07, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement s...

GlobeNewsWire - 2 weeks ago

JENA, Germany, Jan. 05, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system...

InvestorPlace - 2 months ago

With the pandemic drawing much attention toward biotech stocks, there are some interesting ideas among in the small-cap field, but only if you understand the severe risks involved. The post 7 ...

Other stocks mentioned: CANF, FPRX, GTBP, TNXP, VTVT, VXRT
GlobeNewsWire - 2 months ago

JENA, Germany, Oct. 29, 2020 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system...

InvestorPlace - 3 months ago

It wasn't just toilet paper that was in demand when Covid-19 hit us as short-term stocks flew through the roof. But with a second wave upon us, this narrative looks very compelling.

Other stocks mentioned: AMWL, BABA, GME, SNE, SWBI, VBIV
GlobeNewsWire - 4 months ago

JENA, Germany, Sept. 17, 2020 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement sys...

GlobeNewsWire - 4 months ago

JENA, Germany, Sept. 14, 2020 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement sys...

GlobeNewsWire - 5 months ago

JENA, Germany, July 30, 2020 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement syst...

Zacks Investment Research - 5 months ago

Investors need to pay close attention to InflaRx (IFRX) stock based on the movements in the options market lately.

GlobeNewsWire - 5 months ago

JENA, Germany, July 21, 2020 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement syst...

Zacks Investment Research - 6 months ago

InflaRx has been struggling lately, but the selling pressure may be coming to an end soon.

GlobeNewsWire - 7 months ago

JENA, Germany, June 17, 2020 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement syst...

Zacks Investment Research - 7 months ago

InflaRx (IFRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 7 months ago

Europe stocks rally on hopes that the European Union will unveil large stimulus package to reduce the economic fallout from the coronavirus pandemic.

Other stocks mentioned: BAYRY, IPHA
GlobeNewsWire - 7 months ago

JENA, Germany, May 21, 2020 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement syste...

24/7 Wall Street - 9 months ago

InflaRx N.V. (NASDAQ: IFRX) shares jumped early on Wednesday after the company announced that it has enrolled its first patient into a clinical trial for the treatment of severe COVID-19-induc...

GlobeNewsWire - 9 months ago

JENA, Germany, March 31, 2020 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complemen...

GlobeNewsWire - 10 months ago

JENA, Germany, Feb. 26, 2020 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement...

Zacks Investment Research - 1 year ago

InflaRx has been on a bit of a cold streak lately.

Seeking Alpha - 1 year ago

InflaRx's drug IFX-1 performed equal or worse in patient groups compared to a placebo in Phase II clinical trial for skin disorder Hidradentis Suppurativa.

Other stocks mentioned: CCXI
Benzinga - 1 year ago

Shares of the thinly traded, micro-cap biotech Inflarx NV (NASDAQ: IFRX) were losing 90 percent of their value Wednesday following a failed clinical trial.

24/7 Wall Street - 1 year ago

InflaRx N.V. shares were destroyed on Wednesday after the firm announced results from its midstage trial in patients suffering from moderate to severe hidradenitis suppurativa (HS).

Market Watch - 1 year ago

Shares of InflaRx fell 84% in premarket trade Wednesday after the biotech said its drug for an inflammatory skin disorder called hidradenitis suppurativa failed to show a statistically signif...

Zacks Investment Research - 1 year ago

InflaRx N.V. (IFRX) delivered earnings and revenue surprises of 30.65% and -100.00%, respectively, for the quarter ended March 2019.

Zacks Investment Research - 1 year ago

InflaRx (IFRX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

About IFRX

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammat... [Read more...]

Industry
Biotechnology
IPO Date
Nov 8, 2017
CEO
Dr. Niels C. Riedemann M.D., Ph.D.
Employees
43
Stock Exchange
NASDAQ
Ticker Symbol
IFRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for InflaRx N.V. stock is "Hold." The 12-month stock price forecast is 9.68, which is an increase of 64.49% from the latest price.

Price Target
$9.68
(64.49% upside)
Analyst Consensus: Hold